课题基金 / 基金详情

Personalized medicine for schizophrenia: developing neuropsychological tests at first episode to predict treatment resistance

Personalized medicine for schizophrenia: developing neuropsychological tests at first episode to predict treatment resistance
精神分裂症的个性化医疗:在首次发作时进行神经心理学测试以预测治疗耐药性
批准号:
2065232
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2018
资助国家:
英国
项目状态:
已结题
起止时间:
2018 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
30%的精神分裂症患者对至少两种抗精神病药物[难治性精神分裂症(TRS),占NHS精神卫生总资金的25%-50%]没有反应。氯氮平是治疗TRS的金标准,但最近的证据表明,当治疗延迟时,对氯氮平的有效率降低,SLAM的平均延迟为4年。因此,及早识别TRS是至关重要的,这样才能迅速给予个性化治疗。有新的证据表明,使用PET和MRS等神经化学成像可以从首发病程中识别TRS。然而,这种检查对患者来说既昂贵又繁重,限制了其在临床实践中的应用。神经心理学检查费用低廉,耐受性好,有很大的潜力,单独或与血液生物标记物结合,将患者分为TRS亚型和非TRS亚型。拟议的博士学位将:(1)结合来自首发精神病研究的现有数据:i.MRC:精神分裂症和其他精神病的病因学和种族:?SOP(N=402);NIHR BRC遗传学与精神病:GAP(N=246);MRC MICA:精神分裂症的治疗阻力和治疗进展:(STRATA)(N=492)(2)确定神经心理学预测因素,区分治疗反应型精神分裂症、早发性TRS和晚发型TRS,以便(3)为结合遗传和其他数据预测精神分裂症治疗反应的多模式方法的设计提供信息。
英文摘要
30% of patients with schizophrenia fail to respond to at least 2 antipsychotics [Treatment resistant schizophrenia (TRS), accounting for 25-50% of total NHS funding for mental health]. Clozapine is the gold-standard treatment for TRS, but recent evidence shows that the probability of response to clozapine diminishes when treatment is delayed, and that the mean delay in SLAM is 4 years. Early identification of TRS is therefore crucial, so that personalised treatment can be given quickly. There is emerging evidence that TRS can be identified from first episode using neurochemical imaging such as PET and MRS. However, such investigations are costly and burdensome for patients, limiting their utility in clinical practice. Neuropsychological investigations are inexpensive, well tolerated and have great potential, alone or in combination with blood biomarkers, to stratify patients into TRS and non-TRS subtypes. The proposed PhD will:(1) combine existing data from first episode psychosis studies:i. MRC: Aetiology and Ethnicity in Schizophrenia and Other Psychoses: ÆSOP (N=402);ii. NIHR BRC Genetics and Psychosis: GAP (N=246); iii. MRC MICA: Schizophrenia Treatment Resistance and Therapeutic Advances: (STRATA) (N=492) (2) identify neuropsychological predictors distinguishing between treatment-responsive schizophrenia, early-onset TRS and late-onset TRS, in order to(3) inform the design of a multi-modal approach combining genetic and other data to predict treatment response in schizophrenia.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1017/s0033291721004128
发表时间: 2022-01
期刊: Psychological medicine
影响因子: 6.9
作者: [Millgate E, Hide O, Lawrie SM, Murray RM, MacCabe JH, Kravariti E]
通讯作者: Kravariti E
DOI: 10.1136/bmjopen-2022-062570
发表时间: 2022-11-21
期刊: BMJ OPEN
影响因子: 2.9
作者: [Millgate, Edward, Griffiths, Kira, Egerton, Alice, Kravariti, Eugenia, Casetta, Cecilia, Deakin, Bill, Drake, Richard, Howes, Oliver D., Kassoumeri, Laura, Khan, Sobia, Lankshear, Steve, Lees, Jane, Lewis, Shon, Mikulskaya, Elena, Oloyede, Ebenezer, Owens, Rebecca, Pollard, Rebecca, Rich, Nathalie, Smart, Sophie, Segev, Aviv, Verena Sendt, Kyra, MacCabe, James]
通讯作者: MacCabe, James
DOI: 10.1136/bmjopen-2021-054160
发表时间: 2021-11-25
期刊: BMJ open
影响因子: 2.9
作者: [Millgate E, Kravariti E, Egerton A, Howes OD, Murray RM, Kassoumeri L, Donocik J, Lewis S, Drake R, Lawrie S, Murphy A, Collier T, Lees J, Stockton-Powdrell C, Walters J, Deakin B, MacCabe J]
通讯作者: MacCabe J
国内基金
海外基金
新型二维/三维双体系癌症研究模型的建立
  • 批准号:
    32070796
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    王霞
  • 依托单位:
Chinese Journal of Integrative Medicine
  • 批准号:
    81224004
  • 项目类别:
    专项基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2012
  • 负责人:
    徐浩
  • 依托单位:
基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
基于循证医学本体论的临床元数据语言研究